Services We Offer

Innovative research

The Aflac Cancer Center is committed to excellence and innovation in pediatric cancer and blood disorders research. We are home to one of the largest clinical trial programs in the country—offering our patients access to some of the most novel treatment options in the country.

Learn more about our research efforts

Clinical trial highlights

The Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta is proud to have participated in the chimeric antigen receptor (CAR) T cell clinical trials for the treatment of pediatric CD19 positive acute lymphoblastic leukemia (ALL) sponsored by Novartis, that resulted in U.S. Food and Drug Administration (FDA) approval of this ground breaking therapy (Tisagenlecleucel—trade name Kymriah).

We are one of a limited number of centers designated as a certified treatment site. Our team has developed expertise in the delivery of this therapy, treating patients across Georgia and from surrounding and remote states. In addition, our research team is adapting this concept to target other brain tumors and neuroblastoma, which we hope to have in open clinical trials to provide options to patients with resistant disease.

AflacLL1602/ENCERT: A Phase 1 trial using everolimus in combination with nelarabine, cyclophosphamide and etoposide in relapsed T cell lymphoblastic leukemia and lymphoma (T-ALL/T-LLy)

Current therapy options for patients with relapsed T-ALL or T-LLy yield only a 30 percent complete remission rate. The addition of everolimus, an mTOR inhibitor with activity in T cell disease, may improve those rates. The study's main goal is to determine a safe pediatric dose of everolimus and establish a safety profile for everolimus when given in combination with standard chemotherapy.

AflacST1603: A Phase 1 study using nab-paclitaxel (Abraxane) in combination with gemcitabine for pediatric relapsed and refractory solid tumors

Relapsed and refractory non-central nervous system (non-CNS) solid tumors have poor outcomes and novel therapies are needed. We hypothesize the combination of gemcitabine and nab-paclitaxel, an albumin-bound, solvent-free taxane that allows higher dosing and shorter infusion duration than solvent-bound taxanes, as well as increased drug delivery to tumors through increased albumin-initiated transcytosis, will improve the anti-tumor efficacy observed with gemcitabine and docetaxel in relapsed and refractory solid tumors. The study's main goal is to determine a safe pediatric dose of nab-paclitaxel, in combination with gemcitabine, and define a toxicity profile for this combination of chemotherapy.

AflacST1402: A Phase I study using simvastatin in combination with topotecan and cyclophosphamide in relapsed and/or refractory pediatric solid and CNS tumors (NCT02390843)

Independent of cholesterol inhibition, simvastatin has been found to inhibit signal transducer and activator of transcription 3 (STAT3). STAT3 is a protein that stimulates chemotherapy resistance, which is a major cause of treatment failure and death among pediatric and adolescent patients. The study's primary objective is to define the toxicity of high dose simvastatin in combination with chemotherapy to treat solid tumors with abnormal STAT3 activation by restoring tumor sensitivity to routine chemotherapeutic agents.

AflacST1501: A Phase 1 study using abemaciclib in children with newly diagnosed diffuse intrinsic pontine glioma, and in children with recurrent and refractory solid tumors, including malignant brain tumors (NCT02644460)

Abemaciclib represents a selective and potent CDK4/6 dual inhibitor with broad anti-tumor activity. There is existing biologic data demonstrating dysregulation of the CDK4/6 pathway in pediatric high-grade tumors, including malignant brain tumors. Presently, there are not any established treatments that provide effective therapy for patients with progressive disease or patients with newly diagnosed diffuse intrinsic pontine gliomas (DIPG). Abemaciclib is an attractive agent for these patients, given the strong preclinical data on blood-brain barrier penetration, oral bioavailability and its anti-tumor activity. The study's primary objective is to estimate the maximum tolerated dose of abemaciclib in this patient population.

AflacST1502: A Phase II study of sirolimus in combination with metronomic chemotherapy in children with recurrent and/or refractory solid and CNS tumors (NCT02574728)

Sirolimus is a potent immunosuppressive drug that has been found to inhibit cell growth and have anti-tumor activity in previous studies involving pediatric solid tumors. This Phase II study will investigate the time of progression in children with recurrent and refractory solid tumors, including brain tumors, when oral sirolimus is given in combination with metronomic chemotherapy.

Our Unique Approach

The Aflac Cancer and Blood Disorders Center is one of the leading childhood cancer and blood disorders programs in the country. Combining the latest proven technology and research with a caring, child-friendly approach, makes the Aflac Cancer Center a top choice for the treatment of common and complex cancer and blood disorder conditions.

Our facilities include:

  • Facilities recognized by the Magnet Recognition Program®
  • 64 inpatient beds (increasing to 81 beds in 2019)
  • 16 HEPA-filtered rooms for BMT inpatients/ private BMT infusion and procedure rooms
  • Private BMT infusion and procedure rooms
  • Two metaiodobenzylguanidine (131I-MIBG) treatment rooms with adjacent parent rooms
  • Outpatient clinics with a full range of procedure, infusion and apheresis services
  • On-site diagnostics, marrow processing lab and pharmacy services
  • Transitional or temporary housing options to meet the needs of traveling families
  • A 13-chair day hospital with expanded patient care hours (combination of private, semi-private and open-area chairs)

Learn more about what makes Children's special

Learn about our Pediatric Hematology/Oncology Fellowship Program

Children’s Receives $20 Million from Peach Bowl, Inc. to Fight Childhood Cancer

Peach Bowl, Inc. is joining the fight against childhood cancer by announcing a historic $20 million gift to the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta. The Peach Bowl has a long history of giving to Children’s Healthcare of Atlanta and was already planning a major gift when the daughter of one of its executives was diagnosed with leukemia. Anna Charles Hollis, the six-year-old daughter of Benji Hollis, the Peach Bowl’s vice president of sales, was diagnosed with acute myeloid leukemia (AML) on April 15, 2018. After a five-month fight, Anna Charles succumbed to the disease and passed away on September 16. Anna Charles’ fight against AML has served to focus the Peach Bowl’s gift and is the inspiration for the Peach Bowl LegACy Fund, named in her honor, and meant to carry on her fight. The overall goal of the Peach Bowl LegACy Fund is to ensure that high-priority novel agents, devices and treatment strategies can be tested in patients at an accelerated pace, eventually leading to additional treatment options for our patients.

Helpful Resources

New patient requests

Request a new patient appointment

Before your visit

Learn how to prepare for your visit to the Aflac Cancer Center, including information about our transitional housing options for families traveling from outside of metro Atlanta.

Get information and tips

Camps, events and support groups

Camps, retreats and other events offer many therapeutic benefits for children and families who are dealing with serious illness.

Camps, events and support groups

Second opinions

We understand you want to be certain your child is receiving the best possible treatment available. Second opinions can help provide the information you need to make an informed decision about the best treatment for your child. 

Learn more about our second opinion services



Learn how you can help make a difference in the life of a child battling cancer or blood disorders.

Join the fight against childhood cancer and blood disorders

Learn more about how Aflac supports us


Egleston hospital

1405 Clifton Road NE

Atlanta, GA 30322

Hughes Spalding hospital

35 Jesse Hill Jr. Drive SE

Atlanta, GA 30303

Scottish Rite hospital

1001 Johnson Ferry Road NE

Atlanta, GA 30342-1605

Children's Medical Office Building at Scottish Rite hospital

5461 Meridian Mark Road NE

Atlanta, GA 30342-1654

Day Hospital at Scottish Rite hospital

1001 Johnson Ferry Road NE Atlanta, GA 30342

Atlanta, GA 30329